Skip to main content

Table 2 Characteristics of Analyzed Population at Year 5 (n = 5,320) with 500 deaths at up to 10 years of follow-up

From: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

  N % Person-Years of Follow-up Deaths per 1,000 Person Years
Sex     
   Female 1,992 37.4 17,221 9.4
   Male 3,328 62.6 28,587 11.8
Age Group, years     
   35-39 25 0.5 214 9.3
   40-49 1,708 32.1 14,995 4.7
   50-59 2,436 45.8 20,954 11.4
   60+ 1,151 21.6 9,644 19.7
Body Mass Index, kg/m2     
   < 25 2,536 47.7 21,849 10.7
   25- 30 2,098 39.4 18,075 10.6
   > = 30 686 12.9 5,884 12.7
Education (years)     
   < 12 639 12.0 5,496 14.0
   12 1,595 30.0 13,735 11.5
   > 12 3,086 58.0 26,577 10.0
Race     
   White 5,136 96.5 44,226 10.6
   Non-White 184 3.5 1,582 19.6
Smoking Status     
   Former 1,386 26.1 12,063 7.5
   Intermittent 627 11.8 5,403 10.2
   Current 3,307 62.2 28,342 12.5
Randomization Group     
   Intervention, Ipratroprium 1,791 33.7 15,470 9.6
   Intervention, Placebo 1,770 33.3 15,271 10.5
   Control 1,759 33.1 15,067 12.7
Stage (pre-bronchodilator)*     
   Stage 3 or 4 341 6.4 2,831 21.5
   Stage 2 3,587 67.4 30,875 11.3
   Stage 1 995 18.7 8,674 7.3
   Restricted 92 1.7 768 15.6
   Normal 305 5.7 2,659 5.6
Stage (post-bronchodilator)*     
   Stage 3 or 4 183 3.4 1,475 29.8
   Stage 2 3,048 57.3 26,237 12.0
   Stage 1 1,242 23.3 10,775 7.2
   Restricted 126 2.4 1,059 13.2
   Normal 721 13.6 6,262 7.8
  1. *Modified chronic obstructive pulmonary disease stage, as defined in methods